Abstract 416P
Background
Ovarian cancer (OC), the most malignant gynecological tumor, exhibits diverse therapeutic responses. Patient-derived in vitro models for drug screening offer an individualized approach to overcome interpatient heterogeneity. Bypassing the limitations of xenografts and organoids, 3D bioprinting (3DP) offers high-throughput, high fidelity, and a drug screening timeline of 8 days, which is of clinical significance. We hereby reported the establishment of patient-derived 3DP-OC models with personalized drug sensitivity results in 41 patients.
Methods
Tumor specimens of newly diagnosed OC patients were collected at Peking Union Medical College Hospital (PUMCH) from 2022-07 to 2023-07, with informed consent and PUMCH ethics committee approval. Tumors were digested into cell suspensions and mixed with GelMA to a final concentration of 1×107cell/mL. 3DP-OC was fabricated by an extrusion-based bioprinter, and treated with a panel of chemo- and targeted therapy drugs in dose gradients at DIV 5. Cell viability was measured by CellTiter-Glo® assay after 72 hours for dose-response curves and IC50.
Results
We have established 3DP-OC in 41 cases, including 34 high-grade serous ovarian cancer, 4 ovarian clear cell carcinoma, 1 ovarian sarcoma, 1 endometrioid carcinoma and 1 neuroendocrine tumor. The success rate was 100% with consistent viability during bioprinting and extended culture of up to 2 weeks. IHC and IF staining verified the comparable expression of OC markers and Ki-67 between 3DP-OC and tumor tissue. Interpatient heterogeneous response of drugs was observed in paclitaxel, carboplatin, cisplatin, doxorubicin, niraparib, olaparib, anlotinib and lenvatinib. Drug synergy of paclitaxel and carboplatin, first-line treatment of OC, were tested on 5 cases with disparate responses. One of which was clear cell carcinoma with frequent clinical resistance to platin-based therapy, urging a necessity of personalized therapy.
Conclusions
We established 3DP-OC on 41 cases with exceptional efficiency. 3DP-OC demonstrated diverse drug responses, underlining its potential for precision medicine. Our ongoing research aims to correlate 3DP-OC drug responses with clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-058), National High Level Hospital Clinical Research Funding (2022-PUMCH-045, 2022-PUMCH-B-034) and National Natural Science Foundation of China (32271470).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract